Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
Shaw R, Yoon JJ, Johnston H, Davidson MB, Siddon AJ, Shallis RM, Chen EC, Burkart M, Oh TS, Iyer SG, Madarang E, Muthiah C, Kassner J, Rampal RK, Guru Murthy GS, Bradley TJ, Abaza Y, Garcia JS, Gupta V, Pettit KM, Odenike O, Patel AA
У данной статьи нет абстракта.
Blood advances, 2025-02-21
